Anaveon, a Swiss biotech firm focused on precision biologics for autoimmune diseases, announced the appointments of Eric Zanelli as Chief Scientific Officer and Jill Jene as Chief Business Officer. These new executives bring extensive expertise in immunology, translational medicine, and corporate strategy, aiming to accelerate Anaveon's clinical development and expand its pipeline. Zanelli will lead scientific efforts including advancing the lead asset ANV200, while Jene will focus on business growth and strategic partnerships. Their leadership is expected to strengthen Anaveon's position in developing targeted therapies for autoimmune and inflammatory diseases.
The Rosen Law Firm is investigating potential securities claims against Putnam Investment Management, LLC, alleging that the company may have provided misleading business information to investors. Investors who purchased Putnam stock-based mutual fun...
Several stocks experienced significant declines today driven by company-specific events. SANUWAVE Health's shares dropped 39.21% despite strong revenue guidance, Twin Vee Powercats fell 30.95% amid a legal investigation, and Gorilla Technology declin...
The phase III ENDURANCE trial showed that two years of lenalidomide maintenance therapy offers the same long-term survival benefit as indefinite treatment for patients with standard-risk multiple myeloma who are not transplant candidates. After nearl...
The stock market saw significant gains driven by corporate announcements and high trading volumes, particularly in battery technology, electric vehicles, and green energy sectors. Electrovaya surged 49.05% after announcing a commercial deal with Amaz...
An Akamai Technologies executive sold 3,100 shares as the company shifts focus from its declining content delivery network business to high-growth cloud infrastructure and cybersecurity services. This strategic pivot is supported by a $1.8 billion, s...
